SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a biopharmaceutical company focusing on breast cancer treatment with a market capitalization of $107 million, has encountered a challenge in its ...
The new patent application covers a multi-functional process that integrates several off-the-shelf devices, including (an) extruder(s), for effective implementation and scaleup of Aduro ...
Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive ...
The Federal Circuit reversed noninfringement findings made under the reverse doctrine of equivalents (RDOE), declining to declare the doctrine subsumed by the 1952 Patent Act, but finding that Ste ...
AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.